RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sino Biopharmaceutical Stock

Sino Biopharmaceutical EBIT 2024

Sino Biopharmaceutical EBIT

6.43 B CNY

Ticker

1177.HK

ISIN

KYG8167W1380

WKN

A0CBDJ

In 2024, Sino Biopharmaceutical's EBIT was 6.43 B CNY, a 8.08% increase from the 5.95 B CNY EBIT recorded in the previous year.

The Sino Biopharmaceutical EBIT history

YEAREBIT (undefined CNY)
2029e-
2028e6.84
2027e6.31
2026e7.55
2025e7.03
2024e6.43
20235.95
20225.69
20214.78
20204.37
20195.25
20184.4
20173.29
20162.79
20152.4
20142.04
20131.41
20121.38
20110.8
20100.77
20090.69
20080.48
20070.26
20060.21
20050.19
20040.28

Sino Biopharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sino Biopharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sino Biopharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sino Biopharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sino Biopharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sino Biopharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sino Biopharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sino Biopharmaceutical’s growth potential.

Sino Biopharmaceutical Revenue, EBIT and net profit per share

DateSino Biopharmaceutical RevenueSino Biopharmaceutical EBITSino Biopharmaceutical Net Income
2029e37.97 B undefined0 undefined6.03 B undefined
2028e36.63 B undefined6.84 B undefined4.13 B undefined
2027e35.2 B undefined6.31 B undefined3.19 B undefined
2026e36.68 B undefined7.55 B undefined3.67 B undefined
2025e33.08 B undefined7.03 B undefined3.15 B undefined
2024e29.92 B undefined6.43 B undefined3.08 B undefined
202326.2 B undefined5.95 B undefined2.33 B undefined
202226.03 B undefined5.69 B undefined2.54 B undefined
202126.86 B undefined4.78 B undefined14.61 B undefined
202023.65 B undefined4.37 B undefined2.77 B undefined
201924.23 B undefined5.25 B undefined2.76 B undefined
201820.89 B undefined4.4 B undefined9.05 B undefined
201714.82 B undefined3.29 B undefined2.17 B undefined
201613.54 B undefined2.79 B undefined1.64 B undefined
201512.16 B undefined2.4 B undefined1.49 B undefined
201410.94 B undefined2.04 B undefined1.34 B undefined
20137.85 B undefined1.41 B undefined822 M undefined
20126.77 B undefined1.38 B undefined724 M undefined
20114.8 B undefined797 M undefined384 M undefined
20103.56 B undefined770 M undefined494 M undefined
20092.86 B undefined687 M undefined350 M undefined
20082.04 B undefined478 M undefined266 M undefined
20071.14 B undefined257 M undefined219 M undefined
2006754 M undefined212 M undefined145 M undefined
2005796 M undefined191 M undefined1.61 B undefined
20041.12 B undefined283 M undefined179 M undefined

Sino Biopharmaceutical stock margins

The Sino Biopharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sino Biopharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sino Biopharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sino Biopharmaceutical's sales revenue. A higher gross margin percentage indicates that the Sino Biopharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sino Biopharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sino Biopharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sino Biopharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sino Biopharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sino Biopharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sino Biopharmaceutical Margin History

Sino Biopharmaceutical Gross marginSino Biopharmaceutical Profit marginSino Biopharmaceutical EBIT marginSino Biopharmaceutical Profit margin
2029e80.95 %0 %15.89 %
2028e80.95 %18.68 %11.28 %
2027e80.95 %17.93 %9.08 %
2026e80.95 %20.59 %10 %
2025e80.95 %21.25 %9.51 %
2024e80.95 %21.48 %10.31 %
202380.95 %22.69 %8.9 %
202282.76 %21.87 %9.77 %
202180.15 %17.79 %54.38 %
202078.08 %18.49 %11.72 %
201979.67 %21.65 %11.4 %
201879.91 %21.05 %43.31 %
201779.14 %22.22 %14.65 %
201679.2 %20.62 %12.09 %
201577.67 %19.7 %12.22 %
201476.41 %18.66 %12.22 %
201377.49 %17.98 %10.48 %
201279.33 %20.44 %10.69 %
201178.5 %16.6 %8 %
201080.79 %21.63 %13.88 %
200980.27 %24.04 %12.25 %
200879.28 %23.47 %13.06 %
200782.29 %22.64 %19.3 %
200681.03 %28.12 %19.23 %
200581.53 %23.99 %202.76 %
200482.26 %25.36 %16.04 %

Sino Biopharmaceutical Aktienanalyse

What does Sino Biopharmaceutical do?

Sino Biopharmaceutical Ltd is a leading biopharmaceutical company in China that focuses on research, development, production, and distribution of medications. The company is headquartered in Hong Kong and is listed on the Hong Kong Stock Exchange. The company was founded in 2000 by Dr. Tse Ping, an experienced entrepreneur in the chemical industry. The goal was to develop innovative medications that could improve people's health and lives. Since then, Sino Biopharmaceutical has become a major player in the pharmaceutical industry. Sino Biopharmaceutical's business model is based on three pillars: generics, innovative medications, and contract manufacturing. The company specializes in the development and production of generics to make affordable, high-quality medications accessible to the masses. At the same time, the company also invests in research and development of innovative medications for rare and serious diseases. Additionally, Sino Biopharmaceutical also offers contract manufacturing services to other companies. Sino Biopharmaceutical operates in four divisions: pharmaceutical manufacturing, research and development of biopharmaceutical medications, contract manufacturing, and sales and marketing activities. Pharmaceutical manufacturing includes the production of generics as well as the manufacturing of medications for specific indications. Research and development of biopharmaceutical medications focuses on the development of therapies for severe and rare diseases. Contract manufacturing involves the manufacturing process from raw material sourcing to packaging medications for other companies. Sales and marketing activities involve positioning and promoting Sino Biopharmaceutical's products in the market. Some of Sino Biopharmaceutical's well-known products include Hengrui Medicine, an anticancer medication used to treat cancer; Yigu, a medication for liver diseases; and Tongbi, a medication for osteoporosis. Sino Biopharmaceutical has a strong presence in the Chinese market, as well as the international market. The company exports its products to over 60 countries worldwide. Sino Biopharmaceutical has also become a key partner for international companies and regularly collaborates with other pharmaceutical corporations to expand their expertise in product development and manufacturing. In summary, Sino Biopharmaceutical Ltd is a major player in the pharmaceutical industry that specializes in the development and production of generics and innovative medications. There is also a focus on contract manufacturing of medications for other companies. The company has a strong presence in the Chinese market and exports its products to over 60 countries. Sino Biopharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Sino Biopharmaceutical's EBIT

Sino Biopharmaceutical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sino Biopharmaceutical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sino Biopharmaceutical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sino Biopharmaceutical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sino Biopharmaceutical stock

How much did Sino Biopharmaceutical achieve in EBIT for the current year?

In the current year, Sino Biopharmaceutical has achieved an EBIT of 6.43 B CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Sino Biopharmaceutical.

How has the EBIT of Sino Biopharmaceutical developed in recent years?

The EBIT of Sino Biopharmaceutical has increased by 8.079% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Sino Biopharmaceutical?

The EBIT of Sino Biopharmaceutical is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Sino Biopharmaceutical pay?

Over the past 12 months, Sino Biopharmaceutical paid a dividend of 0.08 CNY . This corresponds to a dividend yield of about 2.13 %. For the coming 12 months, Sino Biopharmaceutical is expected to pay a dividend of 0.08 CNY.

What is the dividend yield of Sino Biopharmaceutical?

The current dividend yield of Sino Biopharmaceutical is 2.13 %.

When does Sino Biopharmaceutical pay dividends?

Sino Biopharmaceutical pays a quarterly dividend. This is distributed in the months of November, July, October, October.

How secure is the dividend of Sino Biopharmaceutical?

Sino Biopharmaceutical paid dividends every year for the past 26 years.

What is the dividend of Sino Biopharmaceutical?

For the upcoming 12 months, dividends amounting to 0.08 CNY are expected. This corresponds to a dividend yield of 2.22 %.

In which sector is Sino Biopharmaceutical located?

Sino Biopharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sino Biopharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sino Biopharmaceutical from 10/4/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Sino Biopharmaceutical pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Sino Biopharmaceutical in the year 2023?

In the year 2023, Sino Biopharmaceutical distributed 0.1 CNY as dividends.

In which currency does Sino Biopharmaceutical pay out the dividend?

The dividends of Sino Biopharmaceutical are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sino Biopharmaceutical

Our stock analysis for Sino Biopharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sino Biopharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.